Contract development and manufacturing organisation (CDMO), Recipharm, has partnered with Hadasit Medical Research Services and Development to deliver combined clinical, biological and chemical services.
Israel flags
“Developing a drug involves chemical, biological and clinical expertise,” said Dr Sylvia Kachalsky, site manager at Recipharm in Israel. “Our partnership with Hadasit means we can offer these services more efficiently and manage projects seamlessly from development to clinic.”
This partnership forms part of Recipharm’s growth plans within the regional market and should enable a more seamless customer experience as pharma products progress through the clinical phases.
“The partnership will support business growth in Israel, giving Recipharm access to the majority of the clinical trials taking place in the country. While the field of chemistry services is relatively new to this market, the growth potential is substantial, with more than 800 biotech companies in Israel and the number and size of these companies continuing to grow,” continued Kachalsky. “By collaborating with one of the most prestigious hospitals in the region and its commercial arm, we believe this will support our goal to become the most trusted CDMO in the region.”
“Through the partnership we will be able to offer a full service for the synthesis and testing of compounds,” added Dr Tamar Raz, CEO at Hadasit. “Working with Recipharm, our team will gain professional input regarding the compounds that Hadassah researchers and Hadasit companies are developing, including synthesis and medicinal chemistry challenges. We are looking forward to a mutually beneficial long-term partnership which will ultimately help both companies to grow and support the pharmaceutical industry in Israel.”